Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.

about

2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).

P2860

Q46159136-C63162A9-C5A4-4F64-9AAF-B112B7EBAFD7

P2860

Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.

Item

http://www.wikidata.org/entity/Q50995227

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Novel drug and soluble target ...... es bearing the P329G mutation.

@en

Novel drug and soluble target ...... es bearing the P329G mutation.

@nl

type

Item

label

Novel drug and soluble target ...... es bearing the P329G mutation.

@en

Novel drug and soluble target ...... es bearing the P329G mutation.

@nl

prefLabel

Novel drug and soluble target ...... es bearing the P329G mutation.

@en

Novel drug and soluble target ...... es bearing the P329G mutation.

@nl

P1476

Novel drug and soluble target ...... es bearing the P329G mutation.

@en

P2093

Eginhard Schick

http://www.w3.org/2001/XMLSchema#string

Frank Kowalewsky

http://www.w3.org/2001/XMLSchema#string

Julia Heinrich

http://www.w3.org/2001/XMLSchema#string

Kay Stubenrauch

http://www.w3.org/2001/XMLSchema#string

Mirko Ritter

http://www.w3.org/2001/XMLSchema#string

Uwe Wessels

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes

Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.

The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy.

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

IgG subclasses and allotypes: from structure to effector functions.

Engineered antibody Fc variants with enhanced effector function.

Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies.

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Functional characteristics of the high affinity IgG receptor, FcγRI.

P304

849-859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO-2017-0048

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28517957

http://www.w3.org/2001/XMLSchema#string

Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.

about

P2860

P2860

Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698